Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
EGLT's Cash to Debt is ranked higher than
90% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. EGLT: No Debt )
EGLT' s 10-Year Cash to Debt Range
Min: 0.91   Max: No Debt
Current: No Debt

Equity to Asset 0.79
EGLT's Equity to Asset is ranked higher than
82% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. EGLT: 0.79 )
EGLT' s 10-Year Equity to Asset Range
Min: 0.79   Max: 0.85
Current: 0.79

0.79
0.85
Z-Score: 4.44
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -2957.51
EGLT's Operating margin (%) is ranked higher than
55% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. EGLT: -2957.51 )
EGLT' s 10-Year Operating margin (%) Range
Min: -943.77   Max: -440.97
Current: -2957.51

-943.77
-440.97
Net-margin (%) -4025.64
EGLT's Net-margin (%) is ranked higher than
53% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. EGLT: -4025.64 )
EGLT' s 10-Year Net-margin (%) Range
Min: -1031.47   Max: -449.46
Current: -4025.64

-1031.47
-449.46
ROE (%) -129.54
EGLT's ROE (%) is ranked higher than
57% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. EGLT: -129.54 )
EGLT' s 10-Year ROE (%) Range
Min: 0   Max: 0
Current: -129.54

ROA (%) -85.56
EGLT's ROA (%) is ranked higher than
57% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. EGLT: -85.56 )
EGLT' s 10-Year ROA (%) Range
Min: -155.7   Max: -140.37
Current: -85.56

-155.7
-140.37
ROC (Joel Greenblatt) (%) -1466.27
EGLT's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. EGLT: -1466.27 )
EGLT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1137.7   Max: -674.1
Current: -1466.27

-1137.7
-674.1
» EGLT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

EGLT Guru Trades in

EGLT Guru Trades in

EGLT Guru Trades in

Q1 2014

EGLT Guru Trades in Q1 2014

Steven Cohen 31,594 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with EGLT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.20
EGLT's P/B is ranked higher than
77% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. EGLT: 5.20 )
EGLT' s 10-Year P/B Range
Min: 1.41   Max: 5.2
Current: 5.2

1.41
5.2
P/S 151.30
EGLT's P/S is ranked higher than
67% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. EGLT: 151.30 )
EGLT' s 10-Year P/S Range
Min: 53   Max: 603
Current: 151.3

53
603
PFCF 4.90
EGLT's PFCF is ranked higher than
100% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EGLT: 4.90 )
EGLT' s 10-Year PFCF Range
Min: 1.33   Max: 10.05
Current: 4.9

1.33
10.05
POCF 3.78
EGLT's POCF is ranked higher than
100% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EGLT: 3.78 )
EGLT' s 10-Year POCF Range
Min: 1.04   Max: 16.45
Current: 3.78

1.04
16.45
EV-to-EBIT -2.85
EGLT's EV-to-EBIT is ranked lower than
53% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EGLT: -2.85 )
EGLT' s 10-Year EV-to-EBIT Range
Min: -6.8   Max: -0.3
Current: -2.85

-6.8
-0.3
Current Ratio 12.74
EGLT's Current Ratio is ranked higher than
91% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. EGLT: 12.74 )
EGLT' s 10-Year Current Ratio Range
Min: 0.59   Max: 29.19
Current: 12.74

0.59
29.19
Quick Ratio 12.74
EGLT's Quick Ratio is ranked higher than
91% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. EGLT: 12.74 )
EGLT' s 10-Year Quick Ratio Range
Min: 0.59   Max: 29.19
Current: 12.74

0.59
29.19
Days Sales Outstanding 133.37
EGLT's Days Sales Outstanding is ranked higher than
72% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. EGLT: 133.37 )
EGLT' s 10-Year Days Sales Outstanding Range
Min: 56.56   Max: 107.28
Current: 133.37

56.56
107.28

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.80
EGLT's Price/Net Cash is ranked higher than
89% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. EGLT: 5.80 )
EGLT' s 10-Year Price/Net Cash Range
Min: 2.15   Max: 4.09
Current: 5.8

2.15
4.09
Price/Net Current Asset Value 5.80
EGLT's Price/Net Current Asset Value is ranked higher than
88% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. EGLT: 5.80 )
EGLT' s 10-Year Price/Net Current Asset Value Range
Min: 2.13   Max: 4.06
Current: 5.8

2.13
4.06
Price/Tangible Book 5.10
EGLT's Price/Tangible Book is ranked higher than
82% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. EGLT: 5.10 )
EGLT' s 10-Year Price/Tangible Book Range
Min: 1.9   Max: 3.71
Current: 5.1

1.9
3.71
Price/Median PS Value 1.20
EGLT's Price/Median PS Value is ranked higher than
83% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. EGLT: 1.20 )
EGLT' s 10-Year Price/Median PS Value Range
Min: 0.46   Max: 3
Current: 1.2

0.46
3
Earnings Yield (Greenblatt) -35.00
EGLT's Earnings Yield (Greenblatt) is ranked higher than
59% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. EGLT: -35.00 )
EGLT' s 10-Year Earnings Yield (Greenblatt) Range
Min: -38   Max: 0
Current: -35

-38
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
» More Articles for EGLT

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nasdaq stocks posting largest percentage increases Mar 04 2015
Egalet (EGLT) Falls: Stock Goes Down 7.7% - Tale of the Tape Feb 24 2015
EGALET CORP Files SEC form 8-K, Other Events Feb 12 2015
Egalet (EGLT) Looks Good: Stock Moves 9.3% Higher - Tale of the Tape Feb 05 2015
NASDAQ, NYSE, and OTC-listed Companies Webcast Live to Investors: February 5 at... Feb 02 2015
Egalet to Present at Upcoming Conferences in February Feb 02 2015
Egalet to Present at Upcoming Conferences in February Feb 02 2015
Egalet to Present at Upcoming Conferences in February Feb 02 2015
Egalet (EGLT) Stock Gains Today on Price Target Increase Jan 26 2015
Strength Seen in Egalet (EGLT): Stock Soars 23.9% - Tale of the Tape Jan 23 2015
EGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 22 2015
Egalet Announces Positive Top-Line Results from Oral Human Abuse Liability Study of Abuse-Deterrent... Jan 22 2015
Egalet Announces Positive Top-Line Results From Oral Human Abuse Liability Study of Abuse-Deterrent... Jan 22 2015
EGALET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... Jan 13 2015
EGALET CORP Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure,... Jan 12 2015
ORYZON Appoints Greg Weaver as Global Chief Financial Officer Jan 12 2015
Egalet Appoints Deanne F. Melloy as Chief Commercial Officer Jan 09 2015
Egalet Appoints Deanne F. Melloy as Chief Commercial Officer Jan 09 2015
Egalet Acquires/Licenses Two Innovative Approved Pain Products Jan 08 2015
Egalet Acquires/Licenses Two Innovative Approved Pain Products Jan 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK